share_log

石藥集團：一間附屬公司截至2023年12月31日止年度之主要財務資料

CSPC PHARMA: KEY FINANCIAL INFORMATION OF A SUBSIDIARY FOR THE YEAR ENDED 31 DECEMBER 2023

香港交易所 ·  Jan 24 06:28
Summary by Moomoo AI
石藥集團有限公司（「石藥集團」）於2024年1月24日通知股東及潛在投資者，其間接非全資附屬公司石藥創新制藥股份有限公司（「石藥創新」）擬向石藥集團若干間接全資附屬公司收購石藥集團百克（山東）生物製藥股份有限公司（「石藥百克」）100%股權的建議。石藥百克專注於創新生物製藥的研究、開發及商業化，主要產品為津優力®。石藥百克的財務資料顯示，截至2023年12月31日止年度，總資產為人民幣4,718,695.4千元，總負債為634,819.8千元，公司擁有人應佔權益為4,083,875.6千元，營業收入為2,663,363.6千元，淨利潤為859,018.7千元。石藥集團強調，該財務資料未經審核，且僅反映其中一間附屬公司情況，不代表整體集團狀況。石藥創新與石藥百克的交易條款尚在磋商中，且建議交易須待簽訂正式買賣協議後方可確定，故交易可能未必實現。
石藥集團有限公司（「石藥集團」）於2024年1月24日通知股東及潛在投資者，其間接非全資附屬公司石藥創新制藥股份有限公司（「石藥創新」）擬向石藥集團若干間接全資附屬公司收購石藥集團百克（山東）生物製藥股份有限公司（「石藥百克」）100%股權的建議。石藥百克專注於創新生物製藥的研究、開發及商業化，主要產品為津優力®。石藥百克的財務資料顯示，截至2023年12月31日止年度，總資產為人民幣4,718,695.4千元，總負債為634,819.8千元，公司擁有人應佔權益為4,083,875.6千元，營業收入為2,663,363.6千元，淨利潤為859,018.7千元。石藥集團強調，該財務資料未經審核，且僅反映其中一間附屬公司情況，不代表整體集團狀況。石藥創新與石藥百克的交易條款尚在磋商中，且建議交易須待簽訂正式買賣協議後方可確定，故交易可能未必實現。
Petropharmaceuticals Group Limited (the “Petropharmaceuticals Group”) informed shareholders and potential investors on 24 January 2024 that its indirect non-wholly owned subsidiary Petrol Innovative Pharmaceutical Co., Ltd. (“Petrol Innovations”) intends to acquire from certain indirect wholly-owned subsidiaries of Petropharmaceuticals Group Bio (Shandong) Biomaterials Proposal for 100% shareholding in Pharmaceutical Co., Ltd. (“Petropharmacy Inc.”). Petropharmacy focuses on the research, development and commercialization of innovative biopharmaceuticals. The main product is Tsuyuli®. Petrol 100's financial data show that for the year ended December 31, 2023, total assets were RMB4,718,695.4 thousand, total liabilities were RMB634,819.8 thousand, company owners' equity was RMB 4,083,875.6 thousand, operating income was 2,663,363.6 thousand and net profit was $859,018.7 thousand. The Group stresses that the financial information is unaudited and reflects only the situation of one of its subsidiaries and does not represent the overall situation of the Group. The terms of the transaction for PDO Innovative and PetroChina are still under negotiation, and the proposed transaction is subject to confirmation after the signing of a formal purchase and sale agreement, so the transaction may not be completed.
Petropharmaceuticals Group Limited (the “Petropharmaceuticals Group”) informed shareholders and potential investors on 24 January 2024 that its indirect non-wholly owned subsidiary Petrol Innovative Pharmaceutical Co., Ltd. (“Petrol Innovations”) intends to acquire from certain indirect wholly-owned subsidiaries of Petropharmaceuticals Group Bio (Shandong) Biomaterials Proposal for 100% shareholding in Pharmaceutical Co., Ltd. (“Petropharmacy Inc.”). Petropharmacy focuses on the research, development and commercialization of innovative biopharmaceuticals. The main product is Tsuyuli®. Petrol 100's financial data show that for the year ended December 31, 2023, total assets were RMB4,718,695.4 thousand, total liabilities were RMB634,819.8 thousand, company owners' equity was RMB 4,083,875.6 thousand, operating income was 2,663,363.6 thousand and net profit was $859,018.7 thousand. The Group stresses that the financial information is unaudited and reflects only the situation of one of its subsidiaries and does not represent the overall situation of the Group. The terms of the transaction for PDO Innovative and PetroChina are still under negotiation, and the proposed transaction is subject to confirmation after the signing of a formal purchase and sale agreement, so the transaction may not be completed.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more